NCT01803828View on ClinicalTrials.gov

REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

January 31, 2019

Study Completion Date

July 31, 2019

Conditions
Diabetic CardiomyopathyDiabetes Mellitus Type 2
Interventions
DRUG

Tadalafil

20 mg/die (1 capsule)

DRUG

Placebo

Placebo 20 mg/die (1 capsule)

Trial Locations (1)

00161

Dipartimento di Medicina Sperimentale - Sezione di Fisiopatologia Medica - Sapienza Università di Roma, Rome

All Listed Sponsors
lead

University of Roma La Sapienza

OTHER

NCT01803828 - REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs | Biotech Hunter | Biotech Hunter